Related Experiment Video
Updated: Jun 21, 2026
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo
Xugang Xia1, Hongxia Zhou, Yong Huang
1Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation St, 817 LRB, Worcester, MA 01605, USA. xugang.xia@umassmed.edu
Abstract:
RNA interference (RNAi) has the potential to treat diseases caused by dominant, gain-of-function type of gene mutations. In these diseases, one allele is mutated and produces a toxic protein, whereas the other allele is normal and performs vital functions. One challenge in the treatment is to specifically inhibit the mutant allele toxicity while maintaining the normal allele function. To test allele-specific silencing in vivo, we made transgenic mice that express an shRNA against mutant Cu, Zn superoxide dismutase gene (SOD1(G93A)), which causes amyotrophic lateral sclerosis (ALS) by a gain of an unknown toxic property. By crossing this transgenic line with mice that express SOD1(G93A) and mice that express wild-type human SOD1, we found that this shRNA specifically silences the mutant, but not the wild-type SOD1. The silencing of the mutant significantly delayed ALS onset and extended survival. Thus, RNAi can achieve allele-specific silencing and therapeutic benefit in vivo.
Insights
RNA interference (RNAi) offers a potential treatment for genetic diseases by silencing toxic mutant genes. This study demonstrates that RNAi can specifically target and silence the mutant SOD1 gene, delaying disease progression in amyotrophic lateral sclerosis (ALS) models.
Area of Science:
- Genetics
- Molecular Biology
- Neuroscience
Background:
- Dominant, gain-of-function gene mutations cause diseases by producing toxic proteins.
- Current treatments face challenges in selectively inhibiting mutant alleles while preserving normal gene function.
Purpose of the Study:
- To investigate the potential of allele-specific RNA interference (RNAi) for treating genetic disorders in vivo.
- To assess the efficacy of RNAi in silencing mutant Cu, Zn superoxide dismutase (SOD1) in an amyotrophic lateral sclerosis (ALS) mouse model.
Main Methods:
- Generated transgenic mice expressing short hairpin RNA (shRNA) targeting the mutant SOD1(G93A) gene.
- Crossed these mice with lines expressing either mutant SOD1(G93A) or wild-type SOD1 to test for allele specificity.
- Evaluated the impact of shRNA expression on SOD1 levels, ALS onset, and survival.
Main Results:
- The developed shRNA specifically silenced the expression of the mutant SOD1(G93A) allele.
- Normal, wild-type SOD1 expression remained unaffected by the shRNA.
- Silencing of the mutant SOD1 gene significantly delayed the onset of ALS symptoms and extended survival in the mouse model.
Conclusions:
- RNA interference can achieve effective allele-specific gene silencing in vivo.
- Targeted RNAi therapy shows therapeutic potential for dominant, gain-of-function genetic diseases like ALS.
- This approach offers a promising strategy for treating diseases caused by specific gene mutations.
More Related Videos
08:37A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins
Published on: April 30, 2018
04:41Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Related Concept Videos
01:16In-vitro Mutagenesis
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi